Scope and Claim Analysis for US Patent 9,248,148: Oral Iron Hydroxypyrone Therapy with Elevated Gastric pH
US 9,248,148 is directed to methods of increasing bloodstream iron and treating iron deficiency anemia using an “iron hydroxypyrone” composition, combined with control of gastric acidity (gastric pH maintained >4, with dependent claim ranges >5/>6 and targets around ~6.5+). The claims break into three enforceable control levers: (i) the iron-hydroxypyrone identity, (ii) the gastric pH regime, and (iii) clinical subpopulations where hypochlorhydria/achlorhydria affects absorption.
From a patent landscape perspective, the estate is best positioned against oral iron products where a competitor:
- uses an iron-hydroxypyrone species (including ferric trimaltol or defined hydroxypyrone derivatives), and
- achieves or relies on high gastric pH during absorption, or
- specifically treats achlorhydria by administering without a GI pH lowering agent (claim 9).
What does US 9,248,148 claim to protect: method claims for oral iron and anemia at high gastric pH?
Core independent claim structure (Claim 1 and mirrored Claim 9/12): all three independent themes require:
- Administering a composition comprising an iron hydroxypyrone.
- Achieving a gastric pH condition during the method (Claim 1: maintain gastric pH >4).
- Goal: increase level of iron in bloodstream and/or prevent/treat anemia (explicitly framed around iron deficiency anemia in dependent claims).
Claim 1 scope (highest-level anchor)
Claim 1 covers:
- Method for increasing bloodstream iron and/or preventing/treating anemia
- by administering a composition comprising an iron hydroxypyrone
- with the step of maintaining gastric pH > 4 during the method.
Implication for infringement: a competitor must practice all claim elements as claimed. The “maintaining” limitation can be satisfied by either:
- co-administration that raises gastric pH (or reduces acidity), or
- a clinical scenario where gastric pH is naturally >4, but the claim language still requires the method prescribes the pH condition.
Claim 9 scope (achlorhydria and absence of pH-lowering agent)
Claim 9 covers:
- Administer iron hydroxypyrone to a subject having or at risk of achlorhydria
- where it is administered in the absence of a gastrointestinal pH lowering agent.
Key enforceability angle: this is not only about iron hydroxypyrone + achlorhydria; it also locks in the negative limitation: no GI pH-lowering agent during the method.
Claim 12 scope (inflammatory GI disease + high pH)
Claim 12 covers:
- Administer iron hydroxypyrone and
- maintain gastric pH > 4
- where the subject has an inflammatory disease of the gastrointestinal tract.
This is a population/indication carve with a gastric pH requirement.
How broad are the gastric pH limitations in US 9,248,148 (pH >4 vs >5/>6 vs ~6.5)?
Claim ladder
- Claim 1: gastric pH >4
- Claim 4: gastric pH >5 or 6
- Claim 5: gastric pH about 6.5 or above
- Claim 14: gastric pH >5 or 6
- Claim 15: gastric pH about 6.5 or above
- Claim 19 (specific example): gastric pH >6
Claim construction consequences
- “Greater than 4” is a relatively low threshold, increasing the risk that many real-world “raised pH” situations could fall inside the claim.
- The dependent claims create stronger fallback positions that target moderate-to-high pH regimes, including near-achlorhydric states.
Operational note for design-around
If a competitor targets gastric pH maintained at ≤4, they can avoid Claim 1 and claim families that require >4.
If they accept a high pH but do not use an “iron hydroxypyrone,” they also avoid the core element.
Avoiding only the “~6.5+” dependent targets may not be enough if Claim 1 or Claim 9/12 remains implicated.
What patents protect the “iron hydroxypyrone” composition element in this claim set (including ferric trimaltol and maltol derivatives)?
Claim 6: identity breadth for iron hydroxypyrone
Claim 6 recites a structural/chemical scope:
- ferric complex with hydroxypyrone, or
- mixture of ferrous or ferric salt + hydroxypyrone, where hydroxypyrone is:
- 3-hydroxy-4-pyrone (or a variant with ring carbon substitution by aliphatic hydrocarbon group of 1 to 6 carbons).
This means the “iron hydroxypyrone” term is not limited to a single market product name; it is anchored to hydroxypyrone chemical class plus allowed substitution patterns.
Claim 7: ferric trimaltol and maltol system
Claim 7 narrows to:
- ferric trimaltol or
- an iron (II) or iron (III) carboxylate and maltol.
This creates a high-specificity enforcement lane for competitors using trimaltol/“maltol/iron” technology.
Claim 17: examples of ferrous carboxylate
Claim 17 specifies ferrous carboxylate selection:
- iron (II) gluconate
- iron (II) succinate
- iron (II) fumarate
This dependent claim supports a narrower infringement theory if a competitor uses those carboxylate salts as the iron component with the hydroxypyrone.
How does US 9,248,148 treat “environment where iron is absorbed” (pH >4 outside the stomach)?
Claim 18
Claim 18 adds:
- “the pH of the environment where iron is absorbed is greater than 4.”
This broadens beyond gastric pH (stomach) to the local absorption milieu. If claim construction treats “environment where iron is absorbed” as including parts of the GI tract where pH can be >4, Claim 18 may capture additional real-world dosing scenarios.
Practical impact: even if a competitor argues gastric pH mechanics differ from “absorption environment,” Claim 18 provides an alternate infringement path if their method results in iron absorption from a >4 pH environment.
What additional method limitations appear for subpopulations: achlorhydria, inflammatory disease, and H. pylori?
Claim 11
Achlorhydria associated with:
- inflammatory disease of the GI tract, or
- atrophic gastritis, or
- GI infection such as Helicobacter pylori.
This claim increases coverage for common clinical “high pH by disease state” conditions affecting acid secretion and iron absorption.
Claim 12 and 13/14/15
- Claim 12: inflammatory GI disease + maintain gastric pH >4
- Claim 13: iron deficiency anemia
- Claims 14 and 15: higher gastric pH ranges.
Enforcement theory: competitors pursuing oral iron regimens for inflammatory gastritis/IBD-adjacent anemia may be exposed if their regimen uses iron hydroxypyrone and achieves the specified pH regime.
What is the scope of route and subject type (oral administration, human or animal)?
Claim 2
- Oral administration or “for absorption of iron.”
This is somewhat internally elastic because it recites either an oral route or a conceptual absorption target. In practice, oral iron products are the most direct fit.
Claim 8
This is typical but matters for enforcement strategy in veterinary contexts.
How does US 9,248,148 handle co-administration constraints (absence of pH lowering agents)?
Claim 9’s negative limitation
- iron hydroxypyrone administered in the absence of a gastrointestinal pH lowering agent.
This matters because many oral iron strategies involve agents that raise or lower GI pH depending on the drug’s mechanism. Claim 9 tries to prevent a competitor from arguing their method uses a “pH lowering agent” to create conditions.
Design-around direction: a competitor seeking to use pH modulation may try to structure regimens such that a pH-lowering agent is used, attempting to fall outside Claim 9’s negative limitation. That said, Claim 1 and Claim 12 remain risks if pH >4 is still maintained and an iron hydroxypyrone is used.
Which dosing/presentation “examples” are explicitly locked: ferric trimaltol at pH >6 (Claim 19) and diluents (Claim 20)?
Claim 19
A very specific enforceable lane:
- administer ferric trimaltol
- gastric pH >6
- iron absorbed from ferric trimaltol.
This is a strong infringement target against trimaltol-based oral products where dosing protocols assume gastric pH elevation.
Claim 20
- iron hydroxypyrone administered with pharmaceutically acceptable diluent or carrier.
This is low barrier for competitors because most formulations will include carriers. It mostly prevents trivial arguments that a competitor avoids infringement by changing excipient language.
Claim-by-claim coverage map (what must be done to infringe each numbered claim)
| Claim |
Key additional limitation(s) beyond core concept |
| 1 |
Maintain gastric pH > 4 while administering iron hydroxypyrone for bloodstream iron increase and anemia treatment/prevention |
| 2 |
Administer orally (or method relates to iron absorption) |
| 3 |
Anemia is iron deficiency anemia |
| 4 |
Gastric pH >5 or 6 |
| 5 |
Gastric pH ~6.5+ |
| 6 |
Iron hydroxypyrone defined by hydroxypyrone (3-hydroxy-4-pyrone) with substitution up to C1-C6 aliphatic hydrocarbons, and ferric complex or salt + hydroxypyrone mixture |
| 7 |
Iron hydroxypyrone is ferric trimaltol or iron(II)/(III) carboxylate + maltol |
| 8 |
Human or animal subject |
| 9 |
Subject has or is at risk of achlorhydria; administer without GI pH lowering agent |
| 10 |
Anemia is iron deficiency anemia |
| 11 |
Achlorhydria associated with inflammatory GI disease, atrophic gastritis, or infection like H. pylori |
| 12 |
Subject has inflammatory GI disease; maintain gastric pH >4 |
| 13 |
Anemia is iron deficiency anemia |
| 14 |
Gastric pH >5 or 6 |
| 15 |
Gastric pH ~6.5+ |
| 16 |
Ferrous salt is an iron(II) carboxylate |
| 17 |
Carboxylate examples: gluconate, succinate, fumarate |
| 18 |
pH of environment where iron is absorbed >4 |
| 19 |
Ferric trimaltol; gastric pH >6; absorption from trimaltol |
| 20 |
Administer with pharmaceutically acceptable diluent/carrier |
How strong is the claim scope for forcing a licensing position versus enabling “around-the-edges” design-arounds?
Strength drivers
- Multiple independent anchors (Claims 1, 9, 12) create alternative infringement routes.
- Broad gastric pH threshold in Claim 1 (>4) reduces room for benign “borderline pH” escapes.
- Chemical class definition in Claim 6 can capture variants of hydroxypyrone substitutes, not only a single molecule.
- Claim 19 targets a widely used example framework (ferric trimaltol at high pH).
Weakness/escape surfaces
- If a competitor uses a different iron chelation/macrocycle strategy not falling within “iron hydroxypyrone” as claimed, the entire claim set is avoided.
- If a competitor maintains gastric pH at ≤4 during dosing and avoids the other independent claim paths (achlorhydria scenario may still be risky if it implies gastric pH >4 as practiced), Claim 1/12 risks diminish.
- Claim 9’s “absence of GI pH lowering agent” provides a procedural escape only if a competitor actually introduces a pH-lowering agent as part of the method (and their method still avoids Claims 1 and 12).
What generic entry risks exist for oral iron products in the same mechanistic niche?
High-risk scenario
- Oral administration of an iron hydroxypyrone composition (including trimaltol/maltol-related systems)
- paired with regimens that raise gastric pH (or occur in achlorhydria/atrophic gastritis/H. pylori disease states)
- aimed at iron deficiency anemia correction.
This fits Claims 1/3/9/11/12 depending on population and pH regime.
Lower-risk scenario
- Oral iron strategies that do not use hydroxypyrone-based complexes.
- Or oral methods that rely on iron forms whose absorption does not depend on maintaining gastric pH above 4.
- Or methods that do not produce pH >4 during the administration window.
How do these method claims compare with typical US iron composition patents (and why this one is pH-dependent)?
Many iron-related patent families focus on:
- new iron salts/complexes,
- dosing regimens,
- particle sizes, formulations, or release profiles.
US 9,248,148 is distinct because it makes the method legally dependent on gastric acidity status (and also, in Claim 18, the absorption environment). That pH dependency shifts the infringement question from “what is in the capsule” to “what conditions are created in the GI tract during the method.”
Key Takeaways
- US 9,248,148 protects methods of increasing bloodstream iron and treating or preventing iron deficiency anemia using an iron hydroxypyrone composition with gastric pH control.
- The enforceable pH ladder runs from >4 (independent anchor) to >5/>6 and ~6.5+ (dependent), plus >6 in the ferric trimaltol specific claim.
- Claim scope is split across:
- pH maintenance (Claims 1, 4, 5, 12, 14, 15, 19),
- iron hydroxypyrone identity (Claims 6, 7, 16, 17),
- clinical context (achlorhydria and H. pylori/atrophic gastritis in Claims 9-11; inflammatory GI disease in Claims 12-13).
- Design-arounds must address both levers: the chemical class (iron hydroxypyrone) and the method conditions (gastric pH >4 and, for Claim 9, absence of a GI pH-lowering agent).
FAQs
-
Does US 9,248,148 cover iron hydroxypyrone products administered without directly measuring gastric pH?
The claims require the method step of maintaining gastric pH above specified thresholds; infringement follows the method conditions as practiced.
-
Can achlorhydria alone satisfy the “maintaining gastric pH >4” limitations?
If the clinical state results in gastric pH >4 during dosing, it can satisfy the method’s pH condition for Claims 1/12; Claim 9 focuses on achlorhydria plus the absence of GI pH-lowering agents.
-
Is ferric trimaltol explicitly claimed?
Yes. Claim 19 explicitly recites ferric trimaltol with gastric pH >6 and absorption from that complex.
-
What elements matter most for litigation strategy: formulation or regimen?
Regimen and gastric pH conditions matter as much as formulation identity, because the claims are method-based and pH-dependent.
-
What is the cleanest path to reduce exposure under this patent set?
Use an iron therapy that does not fall within the claimed iron hydroxypyrone class or design the clinical method so gastric/absorption environment pH is not maintained above the claimed thresholds.
References (APA)
- United States Patent 9,248,148. (n.d.). Method for increasing iron levels and treating anemia using iron hydroxypyrone and maintaining gastric pH. US patent.
